Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia
Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical prac...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
O. S. Levin [verfasserIn] A. Sh. Chimagomedova [verfasserIn] O. V. Yakovleva [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Медицинский совет - Remedium Group LLC, 2019, (2020), 19, Seite 31-40 |
|---|---|
| Übergeordnetes Werk: |
year:2020 ; number:19 ; pages:31-40 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.21518/2079-701X-2020-19-31-40 |
|---|
| Katalog-ID: |
DOAJ033741778 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ033741778 | ||
| 003 | DE-627 | ||
| 005 | 20230505014215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.21518/2079-701X-2020-19-31-40 |2 doi | |
| 035 | |a (DE-627)DOAJ033741778 | ||
| 035 | |a (DE-599)DOAJcac7243079bf43609e744d16c8a1196b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a O. S. Levin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. | ||
| 650 | 4 | |a parkinson’s disease | |
| 650 | 4 | |a levodopa | |
| 650 | 4 | |a levodopa phobia | |
| 650 | 4 | |a dopamine agonists | |
| 650 | 4 | |a dopamine agonists phobia | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a A. Sh. Chimagomedova |e verfasserin |4 aut | |
| 700 | 0 | |a O. V. Yakovleva |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Медицинский совет |d Remedium Group LLC, 2019 |g (2020), 19, Seite 31-40 |w (DE-627)1760607460 |x 26585790 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g number:19 |g pages:31-40 |
| 856 | 4 | 0 | |u https://doi.org/10.21518/2079-701X-2020-19-31-40 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/cac7243079bf43609e744d16c8a1196b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.med-sovet.pro/jour/article/view/5917 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2079-701X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2658-5790 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2020 |e 19 |h 31-40 | ||
| author_variant |
o s l osl a s c asc o v y ovy |
|---|---|
| matchkey_str |
article:26585790:2020----::yhlgoprisndsaermeooahbaoo |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.21518/2079-701X-2020-19-31-40 doi (DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b DE-627 ger DE-627 rakwb rus O. S. Levin verfasserin aut Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R A. Sh. Chimagomedova verfasserin aut O. V. Yakovleva verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2020), 19, Seite 31-40 (DE-627)1760607460 26585790 nnns year:2020 number:19 pages:31-40 https://doi.org/10.21518/2079-701X-2020-19-31-40 kostenfrei https://doaj.org/article/cac7243079bf43609e744d16c8a1196b kostenfrei https://www.med-sovet.pro/jour/article/view/5917 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 19 31-40 |
| spelling |
10.21518/2079-701X-2020-19-31-40 doi (DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b DE-627 ger DE-627 rakwb rus O. S. Levin verfasserin aut Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R A. Sh. Chimagomedova verfasserin aut O. V. Yakovleva verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2020), 19, Seite 31-40 (DE-627)1760607460 26585790 nnns year:2020 number:19 pages:31-40 https://doi.org/10.21518/2079-701X-2020-19-31-40 kostenfrei https://doaj.org/article/cac7243079bf43609e744d16c8a1196b kostenfrei https://www.med-sovet.pro/jour/article/view/5917 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 19 31-40 |
| allfields_unstemmed |
10.21518/2079-701X-2020-19-31-40 doi (DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b DE-627 ger DE-627 rakwb rus O. S. Levin verfasserin aut Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R A. Sh. Chimagomedova verfasserin aut O. V. Yakovleva verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2020), 19, Seite 31-40 (DE-627)1760607460 26585790 nnns year:2020 number:19 pages:31-40 https://doi.org/10.21518/2079-701X-2020-19-31-40 kostenfrei https://doaj.org/article/cac7243079bf43609e744d16c8a1196b kostenfrei https://www.med-sovet.pro/jour/article/view/5917 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 19 31-40 |
| allfieldsGer |
10.21518/2079-701X-2020-19-31-40 doi (DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b DE-627 ger DE-627 rakwb rus O. S. Levin verfasserin aut Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R A. Sh. Chimagomedova verfasserin aut O. V. Yakovleva verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2020), 19, Seite 31-40 (DE-627)1760607460 26585790 nnns year:2020 number:19 pages:31-40 https://doi.org/10.21518/2079-701X-2020-19-31-40 kostenfrei https://doaj.org/article/cac7243079bf43609e744d16c8a1196b kostenfrei https://www.med-sovet.pro/jour/article/view/5917 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 19 31-40 |
| allfieldsSound |
10.21518/2079-701X-2020-19-31-40 doi (DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b DE-627 ger DE-627 rakwb rus O. S. Levin verfasserin aut Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R A. Sh. Chimagomedova verfasserin aut O. V. Yakovleva verfasserin aut In Медицинский совет Remedium Group LLC, 2019 (2020), 19, Seite 31-40 (DE-627)1760607460 26585790 nnns year:2020 number:19 pages:31-40 https://doi.org/10.21518/2079-701X-2020-19-31-40 kostenfrei https://doaj.org/article/cac7243079bf43609e744d16c8a1196b kostenfrei https://www.med-sovet.pro/jour/article/view/5917 kostenfrei https://doaj.org/toc/2079-701X Journal toc kostenfrei https://doaj.org/toc/2658-5790 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2020 19 31-40 |
| language |
Russian |
| source |
In Медицинский совет (2020), 19, Seite 31-40 year:2020 number:19 pages:31-40 |
| sourceStr |
In Медицинский совет (2020), 19, Seite 31-40 year:2020 number:19 pages:31-40 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Медицинский совет |
| authorswithroles_txt_mv |
O. S. Levin @@aut@@ A. Sh. Chimagomedova @@aut@@ O. V. Yakovleva @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
1760607460 |
| id |
DOAJ033741778 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ033741778</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014215.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2020-19-31-40</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ033741778</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcac7243079bf43609e744d16c8a1196b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. S. Levin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parkinson’s disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">levodopa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">levodopa phobia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dopamine agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dopamine agonists phobia</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. Sh. Chimagomedova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. V. Yakovleva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2020), 19, Seite 31-40</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">number:19</subfield><subfield code="g">pages:31-40</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2020-19-31-40</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cac7243079bf43609e744d16c8a1196b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/5917</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="e">19</subfield><subfield code="h">31-40</subfield></datafield></record></collection>
|
| author |
O. S. Levin |
| spellingShingle |
O. S. Levin misc parkinson’s disease misc levodopa misc levodopa phobia misc dopamine agonists misc dopamine agonists phobia misc Medicine misc R Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| authorStr |
O. S. Levin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760607460 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
26585790 |
| topic_title |
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia parkinson’s disease levodopa levodopa phobia dopamine agonists dopamine agonists phobia |
| topic |
misc parkinson’s disease misc levodopa misc levodopa phobia misc dopamine agonists misc dopamine agonists phobia misc Medicine misc R |
| topic_unstemmed |
misc parkinson’s disease misc levodopa misc levodopa phobia misc dopamine agonists misc dopamine agonists phobia misc Medicine misc R |
| topic_browse |
misc parkinson’s disease misc levodopa misc levodopa phobia misc dopamine agonists misc dopamine agonists phobia misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Медицинский совет |
| hierarchy_parent_id |
1760607460 |
| hierarchy_top_title |
Медицинский совет |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760607460 |
| title |
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| ctrlnum |
(DE-627)DOAJ033741778 (DE-599)DOAJcac7243079bf43609e744d16c8a1196b |
| title_full |
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| author_sort |
O. S. Levin |
| journal |
Медицинский совет |
| journalStr |
Медицинский совет |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
31 |
| author_browse |
O. S. Levin A. Sh. Chimagomedova O. V. Yakovleva |
| format_se |
Elektronische Aufsätze |
| author-letter |
O. S. Levin |
| doi_str_mv |
10.21518/2079-701X-2020-19-31-40 |
| author2-role |
verfasserin |
| title_sort |
mythology of parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| title_auth |
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| abstract |
Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. |
| abstractGer |
Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. |
| abstract_unstemmed |
Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
19 |
| title_short |
Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia |
| url |
https://doi.org/10.21518/2079-701X-2020-19-31-40 https://doaj.org/article/cac7243079bf43609e744d16c8a1196b https://www.med-sovet.pro/jour/article/view/5917 https://doaj.org/toc/2079-701X https://doaj.org/toc/2658-5790 |
| remote_bool |
true |
| author2 |
A. Sh. Chimagomedova O. V. Yakovleva |
| author2Str |
A. Sh. Chimagomedova O. V. Yakovleva |
| ppnlink |
1760607460 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.21518/2079-701X-2020-19-31-40 |
| up_date |
2024-07-03T19:25:50.756Z |
| _version_ |
1803587158810820608 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ033741778</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505014215.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.21518/2079-701X-2020-19-31-40</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ033741778</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJcac7243079bf43609e744d16c8a1196b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. S. Levin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Any common disease (including Parkinson’s disease) is inevitably overgrown with myths. As a result, not scientifically grounded approaches based on the principles of evidence-based medicine, but irrational ideas, especially often of a pharmacophobic nature, begin to dominate in primary clinical practice among doctors and patients. In clinical practice, we can often face to a situation when doctors, dogmatically accepting the principle of delayed initiation of levodopa therapy, for a long time try to guide the patient on other antiparkinsonian drugs, despite the obvious ineffectiveness of such therapy and the increasingly growing immobility of the patient. This phenomenon, based on the irrational beliefs of not only doctors, but also patients in the toxicity of levodopa, is commonly referred to as levodopa phobia. Levodopa phobia, along with the emergence of a new generation of dopamine agonists (DAs), whose ability to delay the development of fluctuations and dyskinesias has been proven in a series of placebo-controlled studies, as well as the erroneous interpretation of the withdrawal syndrome of DAs as evidence of their high effectiveness, have led to the widespread use of this class. drugs. However, the use of DA turned out to be associated with an increased risk of such adverse events as daytime sleepiness, leg edema, impulsive-compulsive disorders, and withdrawal syndrome. All this served as the basis for the appearance of “dopamine agonists phobia”, which can lead to unjustifiably early prescription of levodopa and the development of dyskinesias. What is the optimal way for managementof PD patients today? In our opinion, the patient management formula that doctors should adhere to should be as follows: early prescription of dopaminergic drugs (more often DAs or levodopa) is necessary, which provides a quick possible, albeit incomplete, correction of a motor defect, which would be sufficient to preserve the patient’s motor activity, including his professional activity; as the symptoms increase, an escalation of antiparkinsonian therapy with the sequential addition of levodopa (or DAs), MAO B inhibitors, amantadines is necessary.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parkinson’s disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">levodopa</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">levodopa phobia</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dopamine agonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dopamine agonists phobia</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. Sh. Chimagomedova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">O. V. Yakovleva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Медицинский совет</subfield><subfield code="d">Remedium Group LLC, 2019</subfield><subfield code="g">(2020), 19, Seite 31-40</subfield><subfield code="w">(DE-627)1760607460</subfield><subfield code="x">26585790</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">number:19</subfield><subfield code="g">pages:31-40</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.21518/2079-701X-2020-19-31-40</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/cac7243079bf43609e744d16c8a1196b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.med-sovet.pro/jour/article/view/5917</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-701X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2658-5790</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="e">19</subfield><subfield code="h">31-40</subfield></datafield></record></collection>
|
| score |
7.4018707 |